Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Moleculin Biotech (MBRX), a Phase 3 clinical stage pharmaceutical company, has announced its participation in the H.C.

Rhea-AI Summary

Moleculin Biotech (MBRX), a Phase 3 clinical stage pharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.

Key points:

• Walter Klemp, Chairman and CEO, will present at the conference
• Management will be available for in-person one-on-one meetings with qualified investors
• A video webcast of the presentation will be accessible on-demand from September 9, 2024, at 7:00 AM ET
• The webcast will be available on the Events page in the Investors section of Moleculin's website
• The webcast replay will be archived for 90 days following the event

Argus Session date unavailable

-3.14% session move Open Argus

Details

News Market Reaction – MBRX

The recorded move for MBRX in the trading session of this news was -3.14%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Sept. 3, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C. Wainwright 26^th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (moleculin.com). The webcast replay will be archived for 90 days following the event.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications. 

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302235514.html

SOURCE Moleculin Biotech, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Moleculin Biotech (MBRX) presenting at the H.C. Wainwright Global Investment Conference?

Moleculin Biotech (MBRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September 9-11, 2024 in New York, NY.

Who will be presenting for Moleculin Biotech (MBRX) at the H.C. Wainwright conference?

Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech (MBRX), will present at the H.C. Wainwright 26th Annual Global Investment Conference.

How can investors access Moleculin Biotech's (MBRX) presentation at the H.C. Wainwright conference?

A video webcast of Moleculin Biotech's (MBRX) presentation will be accessible on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event. It will also be available on the Events page in the Investors section of the Company's website.

How long will the webcast of Moleculin Biotech's (MBRX) presentation be available?

The webcast replay of Moleculin Biotech's (MBRX) presentation at the H.C. Wainwright conference will be archived for 90 days following the event.